skip to main content

United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

Download PDF Version

SILVER SPRING, Md., Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) ("United Therapeutics") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: STDY) ("SteadyMed") with a subsidiary of United Therapeutics. Pursuant to the merger, United Therapeutics acquired all of the outstanding ordinary shares of SteadyMed. As a result of the merger, SteadyMed ordinary shares are no longer publicly traded on the NASDAQ Stock Market.

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-completes-acquisition-of-steadymed-ltd-300704754.html

SOURCE United Therapeutics Corporation

Recent Press Releases

04 Nov 2025

United Therapeutics Corporation to Present at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and...
Download pdf

03 Nov 2025

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal DiseaseSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq:...
Download pdf

29 Oct 2025

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended...
Download pdf

15 Oct 2025

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens...
Download pdf

13 Oct 2025

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual...
Download pdf

19 Sep 2025

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study...
Download pdf
view all